Evidence map›Paper›PMID 37781962›Full record

ArticleCancer science2023

Head-to-head comparison of three chelates reveals DOTAGA promising for

Hitomi Sudo, Atsushi B Tsuji, Aya Sugyo, Yosuke Harada, Satoshi Nagayama, Toyomasa Katagiri, Yusuke Nakamura, Tatsuya Higashi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Hitomi SudoDepartment of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Atsushi B TsujiDepartment of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.ORCID https://orcid.org/0000-0003-2726-288X
Aya SugyoDepartment of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Yosuke HaradaOncoTherapy Science, Kawasaki, Japan.
Satoshi NagayamaDepartment of Surgery, Uji Tokushukai Medical Center, Uji, Japan.ORCID https://orcid.org/0000-0001-9632-914X
Toyomasa KatagiriDivision of Genome Medicine, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.ORCID https://orcid.org/0000-0001-5086-7444
Yusuke NakamuraNational Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Japan.
Tatsuya HigashiDepartment of Molecular Imaging and Theranostics, National Institutes for Quantum Science and Technology (QST), Chiba, Japan.
Theranostics (New Zealand) · NZNational Institute of Biomedical Innovation, Health and Nutrition · JPFukuoka Tokushukai Hospital · JPOncoTherapy Science (Japan) · JP

Funding

Japan Society for the Promotion of Science 21K07688
6 · The paper itself

Abstract

To select the most suitable chelate for

Indexed as

Chelating AgentsNeoplasmsAnimalsCyclamsEstersMiceTissue DistributionChelating AgentsCyclamscyclenEstersalpha-particlechelateFZD10Radioimmunotherapytherapeutic nuclear medicine

Identifiers

PMID37781962
PMCPMC10728013
OpenAlexW4387241284

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.